Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16334324 | 0.84 | HSD11B1 (0.45) | ALDH1A1SMN1; SMN2KDM4ENPC1LMNA | |
| SCHEMBL16334477 | 0.81 | MAPT (0.43) | ALDH1A1SMN1; SMN2NPC1LMNAL3MBTL1 | |
| SCHEMBL12048608 | 0.79 | KDM4E (0.45) | ALDH1A1SMN1; SMN2KDM4ENPC1LMNA | |
| SCHEMBL10834448 | 0.79 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2KDM4ENPC1LMNA | |
| SCHEMBL18716442 | 0.78 | — | — | |
| SCHEMBL30792637 | 0.78 | HDAC8 (0.39) | ALDH1A1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL4257786 | 0.78 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2KDM4ENPC1LMNA | |
| SCHEMBL805428 | 0.78 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KDM4ENPC1LMNA | |
| SCHEMBL8883167 | 0.77 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2NPC1L3MBTL1GAA | |
| SCHEMBL802299 | 0.76 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4ENPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567443-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| EP-3239143-B1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEMICAL LTD (KR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | LG CHEM. LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3013796-B9 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2020-07-01 | — | — | EP | disclosed |
| EP-3628661-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEM, LTD. (KR) | 2020-04-01 | — | — | EP | disclosed |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | LG CHEM, LTD. (KR) | 2019-03-05 | — | — | US | disclosed |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2017-12-07 | — | — | US | disclosed |
| EP-3239143-A2 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG Chem, Ltd. (KR) | 2017-11-01 | — | — | EP | disclosed |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-3013796-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209034-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | ALDH1A1 2174/4885SMN1; SMN2 3448/4885KDM4E 3228/4885 |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GIPR | ALDH1A1 2063/4885SMN1; SMN2 4137/4885KDM4E 2597/4885 |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | GPR119, GLP1R, GIPR | ALDH1A1 2063/4885SMN1; SMN2 4137/4885KDM4E 2597/4885 |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | ALDH1A1 2174/4885SMN1; SMN2 3448/4885KDM4E 3228/4885 |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | GPR119, GPR88, FFAR1 | ALDH1A1 1152/4885SMN1; SMN2 4496/4885KDM4E 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.